Scarica l'app Stockscreener
11.29
1.07%
0.12
Dopo l'orario di chiusura:
11.37
0.08
+0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$11.17
Aprire:
$11.27
Volume 24 ore:
2.00M
Relative Volume:
0.67
Capitalizzazione di mercato:
$799.87M
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-4.9087
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
-14.34%
1M Prestazione:
-24.23%
6M Prestazione:
-76.23%
1 anno Prestazione:
-77.51%
Intervallo 1D:
$11.17
$11.61
Intervallo di 1 settimana:
$11.06
$13.30
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
11.29 | 791.37M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Will MoonLake Immunotherapeutics stock gain from strong economy2026 world cup usa national team quarterfinals playmakers low block defense odds analysis preview - ulpravda.ru
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3%Time to Sell? - MarketBeat
(MLTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Responsive Playbooks and the MLTX Inflection - Stock Traders Daily
Why MoonLake Immunotherapeutics stock could rally in 2025Long Setup & Smart Investment Allocation Insights - Улправда
Trend Report: Will MoonLake Immunotherapeutics stock gain from strong economyWeekly Trade Analysis & Risk Managed Trade Strategies - Улправда
Will MoonLake Immunotherapeutics stock rally after Fed decisionsEarnings Beat & Free Reliable Trade Execution Plans - Улправда
Can MoonLake Immunotherapeutics stock hit analyst price targetsJuly 2025 Update & Weekly High Momentum Picks - Улправда
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research - MSN
Is MoonLake Immunotherapeutics stock attractive for income investorsMarket Risk Analysis & Real-Time Volume Analysis Alerts - Bölüm Sonu Canavarı
MoonLake Extends Sonelokimab Data in Psoriatic Arthritis: What Investors Should Watch - TipRanks
Will MoonLake Immunotherapeutics stock reach all time highs in 2025 - DonanımHaber
Can MoonLake Immunotherapeutics stock hit record highs againWeekly Trade Summary & Risk Controlled Daily Trade Plans - DonanımHaber
Panic Selling: Will MoonLake Immunotherapeutics stock gain from strong economy2025 Momentum Check & Real-Time Price Movement Reports - Улправда
Can MoonLake Immunotherapeutics stock sustain free cash flow growth2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
How buybacks impact MoonLake Immunotherapeutics stock valueTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 - ACCESS Newswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.7%Should You Sell? - MarketBeat
Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 - ACCESS Newswire
Contact Levi & Korsinsky by December 15, 2025 Deadline to - GlobeNewswire
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Invest - GuruFocus
2025-12-15 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025Contact Levi & Korsinsky | NDAQ:MLTX | Press Release - Stockhouse
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - marketscreener.com
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – MLTX - marketscreener.com
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX - GuruFocus
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Rutland Herald
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
2025-12-14 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (MLTX) Valuation After Sonelokimab Phase 3 Setback and Emerging Lawsuits - simplywall.st
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
MLTX DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit - TMX Newsfile
2025-12-14 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX SECURITIES LAWSUIT: MoonLake Immunotherapeutics Investors Are Notified to Contact BFA Law Before Tomorrow's December 15 Class Action Deadline - marketscreener.com
2025-12-13 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6%Still a Buy? - MarketBeat
Phase 3 Miss and Fraud Suits Could Be A Game Changer For MoonLake Immunotherapeutics (MLTX) - simplywall.st
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action - GlobeNewswire
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - GlobeNewswire Inc.
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the - GuruFocus
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):